Product News and Recalls

Joint replacement up, despite problems

A recent report in the Boston Globe takes note of a growing trend that involves younger people requesting joint replacement surgery.

More people in the demographic that doctors have dubbed “young actives” – those in the 45-to-64 age group – are getting the surgery not for basic mobility, but to maintain their athletic lifestyles.

The report notes that the number of joint replacements has risen steadily over the last two decades, despite complaints about problems with the procedures and the need for ...

continue reading...

Costs keep women from using birth control devices

Devices such as IUDs are the most effective means of birth control, but few women use them because of the up-front costs, according to a story from the San Francisco Chronicle on Friday.

The story reports a wide range of costs for birth control among uninsured women, from $9 a month for generic pills to $90 a month for some newer brands. And getting a doctor to insert long-term devices such as IUDs can cost anywhere from $600 to $1,000.

According to ...

continue reading...

Recalls a factor in CEO’s departure

An Associated Press story about the imminent retirement of longtime Johnson & Johnson CEO Bill Weldon mentions his company’s succession of product recalls over the last two years.

Weldon became the company’s CEO in 2002.

According to the story, there were more than two dozen recalls of nonprescription drugs and at least two for prescription drugs since 2009.

There were also recalls of about 25 medical devices and consumer products. Federal regulators have had three of the company’s factories under scrutiny, and shut ...

continue reading...

Bayer expects more lawsuits, according to report

Bayer has about 11,300 lawsuits pending from “persons alleged to have suffered personal injuries, some of them fatal” as a result of using the birth control pills Yasmin, Beyaz, and Yaz and their generic versions. And the company is expecting even more.

That’s from Bayer’s annual report, assessing the company’s status for 2011. The report provides a summation of the legal troubles the company has been dealing with over its oral contraceptives, which according to the lawsuits, cause an increased risk ...

continue reading...

Yaz maker Bayer bidding on pricey acquisition

According to Bloomberg, German corporation Bayer is bidding on Pfizer’s animal-health unit.

Bayer’s chief financial officer said last month that the company planned to cut its debt by $1.3 billion to give it more flexibility for a potential takeover.

According to the report, the Pfizer unit could fetch between $14 billion and $18 billion.

See the report here:

http://www.bloomberg.com/news/2012-03-07/bayer-is-said-to-consider-making-offer-for-pfizer-s-animal-health-division.html

Bayer is the manufacturer of Yaz, Yasmin, Beyaz, and Ocella — birth control pills that contain the compound drospirenone.

Those pills have served as the ...

continue reading...

50,000 U.K. patients need yearly testing from hip implant

About 50,000 hip replacement patients in England and Wales will require annual medical tests to ensure that their metal-on-metal hip implants aren’t causing them potentially crippling complications, British newspaper The Independent reports.

That reflects the number of patients with large hip implants who will need annual blood tests to check their metal ion levels, including about 10,000 people with implants manufactured by DePuy, a subsidiary of Johnson & Johnson.

The risk with the metal-on-metal implants – which use a metal coating for ...

continue reading...
Page 313 of 330 «...290300310311312313314315...»